miR has paired its panel of urine-based RNAs with a statistical algorithm for accurate diagnosis of aggressive bladder and prostate cancers, sparing patients with lower-grade tumors from invasive biopsies and unnecessary drug treatments. The company's...

Evox Therapeutics Ltd. (Oxford, U.K.) raised on Sept. 3 £35.5 million ($45.9 million) in a series B round led by Redmile Group. Also participating were GV, Cowen Healthcare Investments, Panacea Healthcare Venture, Borealis Ventures, Oxford...

Evox Therapeutics Ltd. (Oxford, U.K.) raised £35.5 million ($45.9 million) in a series B round led by Redmile Group. Also participating were GV, Cowen Healthcare Investments, Panacea Healthcare Venture, Borealis Ventures, Oxford Sciences Innovation (OSI),...

Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250 million in cash. Exosome shareholders will also be eligible for $325 million in milestones based on future earnings...

Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250 million in cash. Exosome shareholders will also be eligible for $325 million in milestones based on future earnings...

Researchers at the University of California San Diego published the first proof-of-concept data showing Biological Dynamics Inc. 's exosome-on-a-chip platform can isolate the extracellular vesicles and their proteins in under 30 minutes, without damaging them....

Codiak BioSciences Inc. founder Raghu Kalluri has published the first animal data demonstrating exosomes can be used as drug delivery vehicles to treat cancer -- not just diagnose it. The findings also mark the unveiling...

TECHNOLOGY: Diagnostic assays; cell-free assays; plasma markers A five-protein signature in extracellular vesicles isolated from plasma could help diagnose PDAC. The assay involves two steps: addition of patient plasma samples to a gold plasmonic chip-based...

Nanostics Inc. is analyzing biomarkers on tumor-derived vesicles in blood to increase the accuracy of routine prostate cancer screening, and provide a readout of a tumor's aggressiveness. When used with routine PSA screening, the company’s...

Exosomes from donor tissue may provide an early warning of transplant failure that could aid patient treatment. A group from the University of Pennsylvania showed that donor exosome profiles could be measured in transplant patients...